There is no useful marker in screening and early diagnosis for renal cell carcinomas (RCCs), especially in the urine. To screen for specific markers in the urine of RCCs patients, surface enhanced laser desorption and ionization time of flight mass spectrometry (SELDI-TOF-MS) was used and coupled with a tree analysis pattern to develop SELDI protein profiling of urine. Urine samples from 58 RCC patients, 45 healthy volunteers, and 56 patients with other urogenital diseases were analyzed using IMAC-Cu ProteinChip capable of specifically binding metal interesting proteins. Proteomic spectra were generated by mass spectrometry. Bioinformatic calculations were performed with Biomarker Wizard software 3.0 (Ciphergen). Four differentially expressed potential biomarkers from urine were identified with the relative molecular weights of 4020, 4637, 5070, and 5500. The discriminatory classifier with a panel of the four biomarkers determined in the training set could precisely detect 24 of 30 (sensitivity, 80.0%) RCC and 52 of 58 (specificity, 89.6%) non-RCC samples. Furthermore, a sensitivity of 67.8% (19/28) and a specificity of 81.4% (35/43) for the blinded test were obtained when comparing the RCC vs. non-RCC. So SELDI-TOF combined with a tree analysis pattern could potentially serve as a useful tool for diagnosis of RCC by urine samples.
Introduction
Renal cell carcinomas (RCCs) are a heterogeneous group of tumors. RCCs originating from the renal cortex account for 80% to 85% of primary malignancies of the kidney. In most of cases, RCCs occur in sporadic form and only a small fraction shows a recognizable hereditary pattern. Small localized tumors rarely produce symptoms and its diagnosis is often delayed until the disease is well advanced. In contrast to other urological cancers, RCCs are associated with a high degree of metastases (1), and a five-year survival rate of less than 5% (2). No single validated marker has been proven useful in screening, early diagnosis for asymptomatic disease. The identification of diagnostic and prognostic markers, especially in the urine, remains an area of intense investigation.
In recent years, more and more attention has been drawn to the use of proteomics in studying cancers. Proteomics is a powerful biomedical research tool for the presence of proteins in a given condition. Proteomic technologies have been used to study cancers of various organs, including the liver (3, 4) , prostate (5), breast (6), bladder (7, 8), ovary (9), and esophagus (10) and identified hundreds of potential Technology in Cancer Research & Treatment, Volume 7, Number 3, June 2008 markers. Two-dimensional gel electrophoresis (2-DE) has been the classical proteomic tool for protein separation and analysis. Advances have also been made in mass spectrometry to achieve high throughput separation and analysis of proteins (11). One of the recent advances is the ProteinChip system manufactured by Ciphergen Biosystems, Inc. (Fremont, CA). This system is a novel, extremely sensitive, and rapid method to analyze complex mixtures of proteins and peptides based on surface-enhanced laser desorption/ionization (SELDI) technology (11). SELDI ProteinChip systems use these affinity surfaces to retain proteins based on their physical or chemical characteristics. A few examples have demonstrated that SELDI can be used to identify cancer specific protein "fingerprints" in tissue samples. The objective of this study was to establish a discriminatory protein marker panel to diagnose RCCs by using SELDI protein profiling of urine coupled with a tree analysis pattern.
Materials and Methods

Study Groups and Samples
All voided urine samples were collected from patients seen in the Department of Urology, Shanghai Sixth People's Hospital, Shanghai JiaoTong University. Specimens were obtained before treatment, immediately after rising from bed in the morning before taking any medicine and food. The urine samples from healthy controls were also obtained immediately after rising from bed in the morning before taking any food. Urine was subsequently centrifuged (4,000 rpm for 5 minutes) for removal of cellular material. The supernatants were immediately aliquoted and stored at -80 °C until assayed. Protein concentration of the supernatants was estimated using the bicinchoninic acid kit (Pierce, Rockford, IL).
A total of 159 specimens were included in this study. In RCCs group, 58 urine samples were collected before undergoing nephrectomy for later histologically confirmed clear cell RCC with median age of 59 years (range, 46-82 years). The non-cancer (NC) group included samples from both healthy controls (n=45) and from patients with benign urogenital diseases (n=56 patients) which included clinical or pathologically confirmed renal cysts (n=15), ureteropelvic junction obstruction (n=11), urinary tract infections (n=18), renal angiomyolipoma (n=7), and renal calculus (n=5). The median age of the control population was 49 years (range, 36-69 years) ( Table I ). The RCC group was clinically diagnosed by B-mode ultrasonography, CT scan, MRI, and pathologically confirmed. RCC staging was assessed using the Robson staging system (Table I) .
SELDI-TOF-MS Analysis of Urine
Urine samples were thawed and diluted with binding buffer (20mmol/L Tris, PH 4.0, 0.4mol/l NaCl, 0.1% Triton X100) to equal protein concentration (2 mg/ml). Various chip chemistries (hydrophobic, ionic, cationic, and metal binding) were initially performed and evaluated in our study to determine which affinity chemistry provided the best urine profiles in terms of number and resolution of proteins (7, 8) .
The IMAC-Cu metal binding chip was observed to give the ideal results (data not shown). IMAC-Cu chips (Ciphergen Biosystems, Inc.) were coated with 10 μl of 100 mM CuSO 4 on each array, and agitated for 5 min, then followed by two washes with high-performance liquid chromatography grade water. Thereafter, 10 μl of 100 mM sodium acetate was added to each array and shaken for 5 min to remove the unbound copper. The Chip was rinsed again with water (3 times) and put into a bioprocessor (Ciphergen Biosystems, Inc.). The bioprocessor was washed and shaken on a platform shaker at a speed of 250 rpm for 5 min with 200 μl of PBS in each well. This was repeated twice more, and each time the PBS buffer was discarded by inverting the bioprocessor on a paper towel. 50 μl of the diluted urine was added to each spot. The bioprocessor was sealed and shaken on a platform shaker at a speed of 250 rpm for 60 min. After the urine sample was discarded, the PBS washing step was repeated three times. One microliter of saturated sinapinic acid (Sigma) dissolved in 50% acetonitrile containing 0.5% trifluoracetic acid (Sigma) was applied to each chip spot as the energy-absorbing molecule of choice (i.e., the matrix). The energy-absorbing matrix molecules co-crystallize with the absorbed proteins and cause protein analytes to desorb and ionize during the SELDI process. In addition, the matrix transfers laser energy into kinetic energy, helping the proteins to "fly" to the detector. The loaded chip was transferred into the chip reader of the Protein Biology System II SELDI-TOF mass spectrometer (Ciphergen Biosystems, Inc.) to measure the molecular weights of the bound proteins according to an automated data collection protocol. All samples were scanned in the 2-to 20-kDa window. Laser intensity was adjusted according to resultant spectrum intensity and resolution. The time-of-flight spectra was usually generated by averaging 105 laser shots collected in the positive mode at laser intensity 200, detector sensitivity 9, and a focus lag time of 900 ns. Mass accuracy was calibrated externally using the All-in-1 peptide molecular mass standard (Ciphergen Biosystems, Inc.). In addition, all samples were analyzed in triplicate to ensure that proteins detected during an individual run were indeed reproducible and could be discerned from nonspecific peaks.
Protein Peak Detection
All multiparametric analyses were performed using the Ciphergen SELDI software versions 3.0 (Ciphergen Biosystems, Inc.). The mass range from 2,000-20,000 Da was selected for analysis because this range contained the majority of the resolved protein/peptides. The molecular masses from 0-2,000 Da were eliminated from analysis because this area contains adducts and artifacts of the EAM and possibly other chemical contaminants (7, 8) . Peak detection involved (a) baseline subtraction, (b) mass accuracy calibration, and (c) automatic peak detection.
Identification of Differential Expressed Proteins
Mass spectrometry profiles of the IMAC-Cu metal binding chip were aligned electronically and spectral peaks were clustered under the preset conditions of Biomarker Wizard software (version 3.0, Ciphergen Biosystems) with the exception of a minimum peak threshold of 10% of all spectra. The signal-to-noise ratio was set to five. All data were clustered automatically by a supervised fuzzy clustering algorithm. The output chip data of the Biomarker Wizard software was subjected to the trend test to examine whether there were significant differentially expressed proteins/peptides existed in different tumor stages of the training samples.
Data Analysis
The data analysis process followed three steps: protein peak detection and alignment; selection of peaks with the highest discriminatory power; and data analysis using the Biomarker Pattern Software provided by Ciphergen Biosystems, Inc. During the construction of decision tree, the urine samples were divided into two sets: the training set (88 samples including 30 RCC samples and 58 non-RCC samples) and the test set (71 samples including 28 RCC samples and 43 non-RCC samples). Analysis was also divided into two phases: a preliminary phase with construction of tree analysis pattern, and a testing phase with test urine samples. The validity of the tree analysis pattern was then challenged with the test set. The samples were randomly arranged and blinded for the technicians who processed the samples.
Statistical Analysis
Sensitivity is defined as the ratio of the RCC patients that contained the biomarker to the total number of RCC patients included in the study. Specificity is defined as the ratio of the individuals that do not have the protein peak and do not have RCC, to the total number of individuals without RCC.
Decision Tree Classification
Construction of the decision tree classification algorithm was performed as described previously with modifications based on the Biomarker Patterns Software (version 3.0, Ciphergen Biosystems). Classification of terminal nodes is determined by the group ("class") of samples, such as RCC and non-RCC, based on the presence or absence and the intensity of one peak. The splitting process continues until terminal nodes or leaves are produced or further splitting has no gain. Peaks selected by this process to form the splitting rules are the ones that achieve the maximum reduction of cost in the two descendant nodes (8, 12) .
Reproducibility Analyses
The reproducibility of SELDI spectra from spot to spot on a single chip (intra-assay) and between chips (inter-assay) was determined using the urine quality control sample. Four proteins in the range of 2-20 kDa observed on spectra randomly selected over the course of the study were used to calculate the mass and intensity mean CV.
Results
Identification of Specific Urine Proteomic Feature
159 urine samples were assayed by SELDI mass-spectrometry processing on a IMAC-Cu ProteinChip array. The representative protein spectrum demonstrated the protein masses distributed from 2,000 to 20,000 Da of a single urine specimen ( Figure 1 ). As shown, the SELDI technology was particularly effective in resolving the low molecular weight (<10 kDa) proteins and polypeptides. Interestingly, urine samples from RCC patients appeared to contain more protein peaks. A total of 40 peaks were identified between mass/charge (m/z) 2000 to 20,000, a window suitable for high sensitivity detection. However, we determined that proteins with m/z 2790 and 4750 are the two most stable markers which consistently present in the majority of samples irrespective of sample grouping, suggesting that they could be used as internal controls. In addition, we found that intensities for 2 peaks at m/z 4020 ± 5 and 5500 ± 11 detected in the mass spectra were significantly upregulated, whereas two peaks at m/z 4637 ± 8 and 5070 ± 8 were down-regulated in RCC urines compared with control samples (Figure 2 ).
Decision Tree Classification
Analyzing urine specimens from patients with RCC and non-RCC, four qualified protein peaks between 2,000 and 20,000 Da were used to construct the decision tree classification algorithm.
Five terminal nodes were generated in the decision tree (Figure 3) . These discriminatory peaks efficiently split RCC urine specimens into terminal nodes 2 and 4 and non-RCC samples into terminal nodes 1, 3, and 5. Each mass peak showed a mean intensity ratio of RCC vs. non-RCC > 8 and P value < 0.01 (Table II) . Overall, this decision algorithm correctly classified 24 of 30 RCC samples and 52 of 58 non-RCC controls in the training set, yielding a sensitivity and specificity of 80.0% (24/30) and 89.6% (52/58), respectively (Table III) . Furthermore, in an analysis of spectra from the completely blind test set (28 RCC and 43 non-RCC), the pattern correctly predicted the test samples with the sensitivity and specificity of 67.8% (19/28) and 81.4% (35/43), respectively. All fifteen misclassified RCC cases were found in various stage RCC cases, consisting of 7 of Stage I, 5 of stage II, 2 of stage III, and 1 of stage IV tumors, predicting 63.1 to 84.6% of RCC samples in different stage of the disease (Table IV) .
Discussions
SELDI-TOF-MS provides a proteomic high throughput approach that profiles the mass/charge of potential biomarkers. The identification of proteins/peptides of pathophysiologic relevance in crude biological and clinical samples by SELDI-TOF MS has been demonstrated in various cancer studies. SELDI mass spectrometry determines proteomic profiles by separation of samples on metal bars or affinity chips (ProteinChip Array System, Ciphergen) that contain defined surfaces (i.e., hydrophobic, cationic, anionic, hydrophilic) or are coated with a specific chemical that binds a subset of the proteins in the sample. The advantages of SELDI are many and include the small sample requirement (1-2 μL per analysis), the high sensitivity, the ability to specifically resolve proteins/ions in the lower molecular-weight range and its ability to perform rapid and reproducible protein profiling directly from saliva, urine, se- rum, and other samples (6) (7) (8) (12) (13) (14) (15) . Urine represents a particularly useful fluid in urological cancers because of its enhanced potential containing higher concentrations of directly released tumor-derived products, and additionally its collection is noninvasive. Proteomics analysis of RCCs reported using renal tissues and peripheral blood have yielded some potential markers (1, 2, (12) (13) (14) 16) . Rogers et al. (17) firstly examined the urine from RCC patients using weak cation exchange (WCX2) chip (SELDI-TOF technology), which specifically capture positively charged proteins and achieved in sensitivity and specificity values of 98.3-100% in training test based on either presence/absence of peaks or peak intensity values, and resulted sensitivity and specificity of 81.8-83.3% when using the "blind" group of samples. The robustness of the approach was subsequently evaluated with a group of 80 samples analyzed "blind" 10 months later, (36 patients with RCC, 31 healthy volunteers, and 13 patients with benign urological conditions). However, sensitivities and specificities declined markedly, ranging from 41.0% to 76.6%.
In this study, we use this novel proteomic approach for the detection of RCC in urine. We analyzed urine samples from 58 cases of RCC, 45 normal controls, and 56 cases of non-RCC urinary diseases using IMAC-Cu chip which specifically capture the proteins with affinity for copper. Four differentially expressed potential biomarkers from urine were identified with the relative molecular weights of 4020, 4637, 5070, and 5500. The m/z 5070 protein was also detected that decreased in clear cell RCC by Rogers et al. (17) using WCX2 chip. They thought this peptide was one of the presence of β defensin-1 in urine. The reason for the decrease or relative absence in RCC urines may reflect increased proteolysis or alternatively decreased production, because complete loss of defensin expression has been shown in clear cell tumors (18). However, the proteomic analysis of urine faced more technical challenges because of the several hundred-fold dilute protein concentration compared with serum, the presence of proteases, the variability of protein concentration, and the potential contamination from seminal or vaginal fluids. In our experience, we found that the peaks at m/z 2790 and 4750 are consistently stable in the mass spectra among all protein peaks in the range of m/z 2000 to 20,000, these can potentially be used as internal controls to ensure the quality of the samples. Rogers et al. (17) also found three peaks that consistently present in the majority of samples irrespective of sample grouping, one of which is the m/z 4753 peptide, very close to the masses of the peaks seen here at 4750.
Although one of the goals of this study was to identify tumor markers in the urine that could be used for early detection of renal cancer, the sensitivity was low, 63.1%, in the detection of stage III renal cancer. However, this methodology provided the ability to determine the unique protein fingerprint of a population of tumor cells from the background "noise" of the normal cellular population. This might prove to be of high utility in diagnostic applications, particularly in the context of the low sensitivity of traditional methods for diagnosing RCC.
In conclusion, we suggest that the ability of this method to detect and discriminate multiple protein changes has the potential to improve the urinary diagnosis of RCC. However, the differential protein pattern as the discriminator between RCC and non-RCC is independent of protein identities. Further studies to investigate the origins and full identities of the discriminating biomarkers are in progress. Characterizing these peaks would certainly help in understanding the biological roles of these proteins/peptides and lead to the development of more direct diagnostic tools and novel therapeutic targets for RCC.
